Health Economics & Reimbursement
Psychedelic-assisted therapies are gaining traction in the health economics domain, with promising findings regarding their efficacy in treating mental health disorders. As the FDA considers approval for compounds like MDMA and psilocybin, the economic implications, including reimbursement models, are increasingly relevant to healthcare systems worldwide.
Key Insights
- 1
Current data indicates that MDMA and psilocybin may be approved by the FDA for therapeutic use by 2027, spotlighting the potential for these treatments to revolutionise care.
- 2
A recent phase 3 study showed significant efficacy for MDMA-assisted therapy in reducing PTSD symptoms, reinforcing its potential as a first-line treatment.
- 3
Economic models suggest that integrating psychedelic therapies into standard care may lead to reduced overall healthcare costs due to their efficacy and the potential for decreased need for ongoing treatments.
- 4
Patient and clinician enthusiasm for psychedelic therapies is high, with a notable willingness to engage in innovative treatment methodologies.
What is Health Economics & Reimbursement?
Psychedelic-assisted therapies leverage compounds such as MDMA and psilocybin to address various mental health conditions, including PTSD and depression. These therapies often involve a guided therapeutic process and significant patient-clinician interaction.
Conditions treated with these therapies typically arise from complex biopsychosocial models, where patients may experience symptoms such as persistent anxiety, flashbacks, and emotional dysregulation, significantly impairing their quality of life.
Current Treatments
Standard-of-care treatments include cognitive behavioural therapy (CBT), antidepressant medications, and psychotherapy, which may not always yield satisfactory results, leading to a growing interest in psychedelic alternatives.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Health Economics & Reimbursement.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| MDMA Strong clinical evidence supports substantial PTSD symptom reduction. | Large | High | Consistent |
| Psilocybin Emerging studies indicate effectiveness for depression and anxiety with a solid safety profile. | Medium | Moderate | Consistent |
| Ketamine Widely studied with rapid antidepressant effects and proven efficacy in treatment-resistant depression. | Medium | High | Consistent |
| Ayahuasca Limited studies hinder a clear consensus on efficacy compared to other compounds. | Small | Low | Inconsistent |
MDMA and Health Economics & Reimbursement
MDMA-assisted therapy, through its empathogenic effects, facilitates enhanced emotional engagement and catharsis during therapy sessions. Patients report significant reductions in PTSD symptoms, often leading to improved functioning and quality of life post-treatment. The effects of MDMA, including reduced fear response and increased feelings of safety and trust, create an optimal environment for therapeutic breakthroughs.
Clinical Outlook
The future of psychedelic treatments appears promising, with ongoing research and upcoming regulatory approvals likely to pave the way for these therapies to become mainstream options for mental health care. As reimbursement frameworks adapt, increased accessibility may foster wider acceptance and utilisation.
Industrial Landscape
Key industry players include MAPS (Multidisciplinary Association for Psychedelic Studies) and various research universities, alongside non-profits focused on mental health advocacy, such as the Beckley Foundation.
Quick Indicators
Organisations
Search →OPEN Foundation
Dutch nonprofit organizer in the psychedelic field, including stewardship of the ICPR conference series and related professional convenings.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
University Medical Centre Groningen
The PsyPal project coordinators at UMCG are leading a major EU-funded multi-site clinical study investigating psilocybin therapy for psychological and existential distress in patients with progressive incurable illnesses, including ALS.
University of Copenhagen
The Neurobiology Research Unit (NRU) at Copenhagen University Hospital has been carrying out clinical and preclinical research with psychedelics since 2017. The team at the NRU utilizes various neuroimaging techniques to better understand how psychedelics exert their effects on the brain. They have published numerous peer-reviewed articles on psychedelics and facilitated numerous medium-dose psilocybin sessions. The NRU is led by Professor Gitte Moos Knudsen.
29k International AB
29k International AB is a Swedish non-profit tech foundation offering a free mental health app with science-based psychological tools and peer support programs, partnering with institutions including Karolinska Institute and Harvard University. The organization has been involved in clinical research as a digital therapeutic support platform in studies exploring mental health outcomes alongside psychedelic and other novel interventions.
American Psychiatric Association
US professional psychiatric body that publishes position statements and guidance relevant to evidence standards and clinical policy considerations for psychedelic and empathogenic therapies.
Bispebjerg Hospital
Bispebjerg Hospital is a major Copenhagen university hospital and the coordinating site for PsyPal, the EU-funded multi-centre trial investigating psilocybin-assisted therapy for anxiety and existential distress in patients with ALS—the first European publicly-funded psychedelic trial of its kind. Affiliated with the University of Copenhagen, the hospital leads Nordic clinical research into psychedelic-assisted therapies for neurological and palliative conditions.
Canisius-Wilhelmina Hospital
Canisius-Wilhelmina Hospital (CWZ) is a major teaching hospital in Nijmegen, Netherlands, whose Department of Neurology has contributed to psychedelic research including an evidence-based review of LSD and psilocybin for chronic pain management, examining serotonin-2A receptor-mediated neuroplastic mechanisms. Situated in the Netherlands—one of Europe’s most active countries for psychedelic research—CWZ participates in neurological research exploring psychedelic compounds as therapeutic agents for pain and psychiatric conditions.
CTC Clinical Trial Consultants AB
Swedish full-service CRO with early-phase concentration, integrated site network, and in-house capabilities spanning project management, monitoring, biometrics, pharmacovigilance, and medical writing.
European Association for Palliative Care (EAPC)
The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.
European Association of Neurological Associations (EFNA)
The European Federation of Neurological Associations (EFNA) is a Brussels-based umbrella organization representing 21 pan-European neurology patient groups, advocating for improved access and resources for people with neurological disorders. EFNA participates as a patient advocacy partner in the PsyPal consortium, the first EU-funded multi-site psilocybin clinical trial (€6.5M) studying psilocybin for psychological distress in palliative care neurological patients.
People
Search →Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Kruti Joshi
Employee at Janssen Scientific Affairs, LLC
Joshi appears to be a Janssen-affiliated researcher coauthoring multiple real-world evidence studies on esketamine access, barriers, utilization, and economic outcomes in treatment-resistant depression.
Michael Ashton
Professor of Clinical Pharmacology at the University of Gothenburg
He is a pharmacometrics and clinical pharmacology researcher whose work has been used in psychedelic studies on DMT pharmacokinetics, pharmacodynamics, EEG effects, and psychedelic intensity modeling.
Scott Tyler Aaronson
Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt; Adjunct Professor of Psychiatry, University of Maryland School of Medicine
He is a leading psychiatrist in treatment-resistant depression and a key investigator on psilocybin studies, including work on preparation, dosing, outcomes, and mechanisms of psychedelic-assisted therapy.
Mark Andrew Frye
Chair, Department of Psychiatry and Psychology, Mayo Clinic (Rochester, Minnesota)
He is a leading mood-disorders psychiatrist whose work has helped shape the clinical evidence base and consensus guidance for ketamine in depression.
Jack Stroud
Clinical Psychologist; Trainee Clinical Psychologist at University College London (UCL)
Jack Stroud is a clinical psychologist and psychedelic researcher whose work spans psilocybin, autism, and psychedelic-related changes in mental health and social functioning.
Michael Grunebaum
Associate Professor of Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute
He is a leading ketamine and suicidality researcher whose clinical trials and meta-analytic work helped shape rapid-acting antidepressant research in psychiatry.
Erwin Krediet
Psychologist and psychedelic researcher at ARQ National Psychotrauma Centre; PhD researcher at Leiden University Medical Center
He is a Dutch psychedelic researcher contributing to clinical studies and educational work on psychedelics, including MDMA-assisted psychotherapy for PTSD and LSD/psilocybin studies.
David Hellerstein
Professor of Clinical Psychiatry at Columbia University Irving Medical Center; Research Psychiatrist at the New York State Psychiatric Institute; Director of the Depression Evaluation Service
He is a principal investigator on psilocybin studies for treatment-resistant depression and related psychiatric conditions, helping establish the clinical evidence base for psychedelic-assisted therapy.
Peter Hendricks
Professor of Health Behaviour and Psychedelic Research
Noted for rigorous population‑level epidemiological analyses elucidating associations between classic psychedelic use and mental and physical health outcomes, and for advancing research on microdosing and adverse psychological responses.
Connected Evidence
The latest clinical data and verified academic findings associated with Health Economics & Reimbursement.